Quadruplet Versus Triplet Regimens in Multiple Myeloma
Sarah Holstein, MD, PhD, explains her rationale for choosing a triplet regimen over a quadruplet in patients with multiple myeloma.
Sarah Holstein, MD, PhD, associate professor at the University of Nebraska Medical Center, explains her rationale for choosing a triplet regimen over a quadruplet in patients with multiple myeloma.
Holstein does not use quadruplet regimens outside of clinical trials because the treatment paradigm is not quite there, she says. However, she tries to use triplet combinations in the majority of her patients.
Fellow's Perspective: Impact of Quadruplet and MRD in Newly Diagnosed Multiple Myeloma
December 17th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma.
Read More
